GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.
Apoptosis
Bladder cancer
GREM1
PI3K/AKT signaling pathway
Progression
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
17
04
2023
accepted:
29
07
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Gremlin-1 (GREM1) is a protein closely related to tumor growth, although its function in bladder cancer (BCa) is currently unknown. Our first objective was to study the GREM1 treatment potential in BCa. BCa tissue samples were collected for the detection of GREM1 expression using Western blot analysis and Immunofluorescence staining. Association of GREM1 expression with clinicopathology and prognosis as detected by TCGA (The Cancer Genome Atlas) database. The functional investigation was tested by qRT-PCR, western blot analysis, CCK-8, cell apoptosis, wound healing, and transwell assays. The interaction between GREM1 and the downstream PI3K/AKT signaling pathway was assessed by Western blot analysis. GREM1 exhibited high expression in BCa tissues and was linked to poor prognosis. Stable knockdown of GREM1 significantly inhibited BCa cell (T24 and 5637) proliferation, apoptosis, migratory, invasive, as well as epithelial-mesenchymal transition (EMT) abilities. GREM1 promotes the progression in BCa via PI3K/AKT signaling pathway. Findings demonstrate that the progression-promoting effect of GREM1 in BCa, providing a novel biomarker for BCa-targeted therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Gremlin-1 (GREM1) is a protein closely related to tumor growth, although its function in bladder cancer (BCa) is currently unknown. Our first objective was to study the GREM1 treatment potential in BCa.
METHODS
METHODS
BCa tissue samples were collected for the detection of GREM1 expression using Western blot analysis and Immunofluorescence staining. Association of GREM1 expression with clinicopathology and prognosis as detected by TCGA (The Cancer Genome Atlas) database. The functional investigation was tested by qRT-PCR, western blot analysis, CCK-8, cell apoptosis, wound healing, and transwell assays. The interaction between GREM1 and the downstream PI3K/AKT signaling pathway was assessed by Western blot analysis.
RESULTS
RESULTS
GREM1 exhibited high expression in BCa tissues and was linked to poor prognosis. Stable knockdown of GREM1 significantly inhibited BCa cell (T24 and 5637) proliferation, apoptosis, migratory, invasive, as well as epithelial-mesenchymal transition (EMT) abilities. GREM1 promotes the progression in BCa via PI3K/AKT signaling pathway.
CONCLUSION
CONCLUSIONS
Findings demonstrate that the progression-promoting effect of GREM1 in BCa, providing a novel biomarker for BCa-targeted therapy.
Identifiants
pubmed: 37605239
doi: 10.1186/s12957-023-03128-0
pii: 10.1186/s12957-023-03128-0
pmc: PMC10463405
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Biomarkers
0
GREM1 protein, human
0
Intercellular Signaling Peptides and Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
255Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Deng G, Wang R, Sun Y, et al. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARgamma/MMP-9 signals. Cell Death Differ. 2021;28:2145–59.
doi: 10.1038/s41418-021-00743-w
pubmed: 34127806
pmcid: 8257744
Hou T, Dan W, Liu T, et al. Deubiquitinase OTUD5 modulates mTORC1 signaling to promote bladder cancer progression. Cell Death Dis. 2022;13:778.
doi: 10.1038/s41419-022-05128-6
pubmed: 36085200
pmcid: 9463452
Rietbergen DDD, van Gennep EJ, KleinJan GH, et al. Evaluation of the hybrid tracer indocyanine green- 99m Tc-nanocolloid for sentinel node biopsy in bladder cancer-a prospective pilot study. Clin Nucl Med. 2022;47:774–80.
doi: 10.1097/RLU.0000000000004301
pubmed: 35713891
pmcid: 9351699
Carrasco R, Ingelmo-Torres M, Gomez A, et al. Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer. World J Urol. 2022;40:2033–9.
doi: 10.1007/s00345-022-04061-9
pubmed: 35713686
pmcid: 9203260
Nakayama M, Ito Y, Hatano K, et al. Impact of sex difference on survival of bladder cancer: a population-based registry data in Japan. Int J Urol. 2019;26:649–54.
doi: 10.1111/iju.13955
pubmed: 30916420
Yang Z, Liu A, Xiong Q, et al. Prognostic value of differentially methylated gene profiles in bladder cancer. J Cell Physiol. 2019;234:18763–72.
doi: 10.1002/jcp.28515
pubmed: 30953370
Gabitova L, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res. 2014;20:28–34.
doi: 10.1158/1078-0432.CCR-13-0122
pubmed: 24158702
Kisonaite M, Wang X, Hyvonen M. Structure of Gremlin-1 and analysis of its interaction with BMP-2. Biochem J. 2016;473:1593–604.
doi: 10.1042/BCJ20160254
pubmed: 27036124
Brazil DP, Church RH, Surae S, et al. BMP signalling: agony and antagony in the family. Trends Cell Biol. 2015;25:249–64.
doi: 10.1016/j.tcb.2014.12.004
pubmed: 25592806
Park SA, Sung NJ, Choi BJ, et al. Gremlin-1 augments the oestrogen-related receptor alpha signalling through EGFR activation: implications for the progression of breast cancer. Br J Cancer. 2020;123:988–99.
doi: 10.1038/s41416-020-0945-0
pubmed: 32572171
pmcid: 7493948
Gazzerro E, Smerdel-Ramoya A, Zanotti S, et al. Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J Biol Chem. 2007;282:31549–57.
doi: 10.1074/jbc.M701317200
pubmed: 17785465
Church RH, Ali I, Tate M, et al. Gremlin1 plays a key role in kidney development and renal fibrosis. Am J Physiol Renal Physiol. 2017;312:F1141–57.
doi: 10.1152/ajprenal.00344.2016
pubmed: 28100499
pmcid: 5495891
Myllarniemi M, Lindholm P, Ryynanen MJ, et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:321–9.
doi: 10.1164/rccm.200706-945OC
pubmed: 17975199
Lavoz C, Alique M, Rodrigues-Diez R, et al. Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway. J Pathol. 2015;236:407–20.
doi: 10.1002/path.4537
pubmed: 25810250
Lavoz C, Poveda J, Marquez-Exposito L, et al. Gremlin activates the Notch pathway linked to renal inflammation. Clin Sci (Lond). 2018;132:1097–115.
doi: 10.1042/CS20171553
pubmed: 29720422
Ouahoud S, Hardwick JCH, Hawinkels L. Extracellular BMP Antagonists, Multifaceted Orchestrators in the Tumor and Its Microenvironment. Int J Mol Sci. 2020;21:3888.
Zeng SX, Zhu YJ, Ma AH, et al. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017;23:6580–91.
doi: 10.1158/1078-0432.CCR-17-0033
pubmed: 28808038
pmcid: 5668181
Zhu SM, Ma AH, Zhu Z, et al. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer. 2021;9:e002917.
Zhang X, Ma ZG, Yuan YP, et al. Rosmarinic acid attenuates cardiac fibrosis following long-term pressure overload via AMPKalpha/Smad3 signaling. Cell Death Dis. 2018;9:102.
doi: 10.1038/s41419-017-0123-3
pubmed: 29367637
pmcid: 5833382
Zhang X, Zhu JX, Ma ZG, et al. Rosmarinic acid alleviates cardiomyocyte apoptosis via cardiac fibroblast in doxorubicin-induced cardiotoxicity. Int J Biol Sci. 2019;15:556–67.
doi: 10.7150/ijbs.29907
pubmed: 30745842
pmcid: 6367577
Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29:212–26.
doi: 10.1016/j.tcb.2018.12.001
pubmed: 30594349
Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–8.
doi: 10.1016/j.gene.2019.02.076
pubmed: 30849534
Martin-Way D, Puche-Sanz I, Cozar JM, et al. Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer. Sci Total Environ. 2022;843: 156965.
doi: 10.1016/j.scitotenv.2022.156965
pubmed: 35764155
Cheng C, Wang J, Xu P, et al. Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. Nat Cancer. 2022;3:565–80.
doi: 10.1038/s43018-022-00380-3
pubmed: 35624341
Kan J, Fu B, Zhou R, et al. He-Chan Pian inhibits the metastasis of non-small cell lung cancer via the miR-205-5p-mediated regulation of the GREM1/Rap1 signaling pathway. Phytomedicine. 2022;94: 153821.
doi: 10.1016/j.phymed.2021.153821
pubmed: 34752967
Davis H, Irshad S, Bansal M, et al. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat Med. 2015;21:62–70.
doi: 10.1038/nm.3750
pubmed: 25419707
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: A Review. JAMA. 2020;324:1980–91.
doi: 10.1001/jama.2020.17598
pubmed: 33201207
Aveta A, Cacciapuoti C, Barone B, et al. The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk? Cancers (Basel). 2022;14:4775.
Al-Zalabani AH, Wesselius A, Yi-Wen YuE, et al. Tea consumption and risk of bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study: Pooled analysis of 12 international cohort studies. Clin Nutr. 2022;41:1122–30.
doi: 10.1016/j.clnu.2022.03.020
pubmed: 35413574
Trang NTN, Lai CY, Tsai HC, et al. Apelin promotes osteosarcoma metastasis by upregulating PLOD2 expression via the Hippo signaling pathway and hsa_circ_0000004/miR-1303 axis. Int J Biol Sci. 2023;19:412–25.
doi: 10.7150/ijbs.77688
pubmed: 36632453
pmcid: 9830518
Cathomas R, Lorch A, Bruins HM, et al. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2022;81:95–103.
doi: 10.1016/j.eururo.2021.09.026
pubmed: 34742583
Monteiro-Reis S, Lobo J, Henrique R, Jeronimo C. Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer. Int J Mol Sci. 2019;20:297.
Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 2019;59:125–32.
doi: 10.1016/j.semcancer.2019.07.009
pubmed: 31323288
Mortazavi M, Moosavi F, Martini M, et al. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol. 2022;176: 103749.
doi: 10.1016/j.critrevonc.2022.103749
pubmed: 35728737
Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–55.
doi: 10.1182/blood-2018-05-850461
pubmed: 30287523
pmcid: 6284216
Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058–70.
doi: 10.1056/NEJMoa2214131
pubmed: 37256976
Sathe A, Nawroth R. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. Methods Mol Biol. 2018;1655:335–50.
doi: 10.1007/978-1-4939-7234-0_23
pubmed: 28889395